Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Fouliard

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Frontiers in Oncology|July 31, 2013
Influence of the duration of intravenous drug administration on tumor uptakeSylvain Fouliard, Marylore Chenel, Fabrizio Marcucci
Journal of Pharmacokinetics and Pharmacodynamics|November 19, 2015
Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessmentSophie Peigné, Sylvain Fouliard, Sophie Decourcelle, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2022
Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mappingThibaud Derippe, Sylvain Fouliard, Xavier Declèves, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 15, 2024
Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3-mimetics using virtual tumors calibrated with cell viability assaysThibaud Derippe, Sylvain Fouliard, Xavier Decleves, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 14, 2015
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessmentSophie Peigné, François Bouzom, Karl Brendel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2021
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approachElena M Tosca, Glenn Gauderat, Sylvain Fouliard, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 17, 2026
PK and PK/PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With MicrodosingChloé Burlot, François Riglet, Mathilde Romagnoli, et al.
Investigational New Drugs|May 31, 2014
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patientsQuentin Chalret du Rieu, Sylvain Fouliard, Mélanie White-Koning, et al.
The AAPS Journal|March 29, 2018
Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
The AAPS Journal|March 9, 2018
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|July 31, 2013
Influence of the duration of intravenous drug administration on tumor uptakeSylvain Fouliard, Marylore Chenel, Fabrizio Marcucci
Journal of Pharmacokinetics and Pharmacodynamics|November 19, 2015
Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessmentSophie Peigné, Sylvain Fouliard, Sophie Decourcelle, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2022
Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mappingThibaud Derippe, Sylvain Fouliard, Xavier Declèves, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 15, 2024
Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3-mimetics using virtual tumors calibrated with cell viability assaysThibaud Derippe, Sylvain Fouliard, Xavier Decleves, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 14, 2015
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessmentSophie Peigné, François Bouzom, Karl Brendel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2021
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approachElena M Tosca, Glenn Gauderat, Sylvain Fouliard, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 17, 2026
PK and PK/PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With MicrodosingChloé Burlot, François Riglet, Mathilde Romagnoli, et al.
Investigational New Drugs|May 31, 2014
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patientsQuentin Chalret du Rieu, Sylvain Fouliard, Mélanie White-Koning, et al.
The AAPS Journal|March 29, 2018
Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
The AAPS Journal|March 9, 2018
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
Pageof 3